A study of verapamil in treatment of keloid

Yogesh M. Shah, Adit M. Garg, Gaurav Paliwal, Amir S. Ansari, Chandni Jain, Rashmi Rastogi


Background: Keloid is a common presentation in clinical practice. Symptoms due to keloid are mild, but disfigurement and functional impairment can be severe. It is difficult to treat. Intralesional, injection triamcinolone acetonide, has limited efficacy, causes adverse effects such as local dermal atrophy, telengiectasia and hypopigmentation. Injection verapamil is reported to have similar efficacy, but lesser side effects, and is cheaper. Aim was to study efficacy and adverse effects of intralesional verapamil in treatment of keloid.

Methods: An open label study on 25 patients of keloid, either gender, age 11 to 55 years at a medical college hospital. Injection verapamil 2.5 mg/ml was administered intralesionally, at an interval of 3 weeks, for a total of 6 sittings, over a period of 18 weeks. Vancouver scar scale (VSS) was used to assess the improvement. The statistical analysis was done using SPSS version 21.0.

Results: Median duration of keloids was 8 months. The mean VSS score before treatment was 7.68 which reduced to 4.28 after treatment. Mean percentage change in VSS score was 46.21%, very highly significant (p<0.001). Physician’s assessment was ‘very good’ in 32.0% and 'excellent' in 8.0%. The complaint of post-procedure pain was present in almost all.

Conclusions: Intralesional injection verapamil, gives very good to excellent improvement in 40% of patients of keloid. Post injection pain persists for more than 24 hours. Drug does not cause local dermal atrophy or hypopigmentation.


Keloids, Intralesional, Verapamil, Efficacy, Vancouver scar scale

Full Text:



Burrows NP, Lovell CR. Disorders of Connective Tissue. In: Burns T, Rook A. Rooks textbook of dermatology. 8th ed. Oxford: Wiley-Blackwell; 2010: 45.54-45.56.

Lemonas P, Ahmad I, Falvey DH, Jimenez G, Myers S. Keloid scars: the hidden burden of disease. J Pigmentary Disorders. 2015; 2:: 231.

Le Flore IC. Misconceptions regarding elective plastic surgery in the black patient. J Natl Med Assoc. 1980;72:947–8.

Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;141:512–7.

Lee S-S, Yosipovitch G, Chan Y-H, Goh C-L. Pruritus, pain, and small nerve fibre function in keloids: a controlled study. J Am Acad Dermatol 2004;51:1002–6.

Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006;297:433–8.

Brown BC, McKenna SP, Siddhi K, McGrouther DA, Bayat A. The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthet Surg. 2008;61:1049–58.

Cruz NI, Korchin L. Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg. 1994;33:401–5.

D'Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of keloids with intralesional verapamil. Dermatology. 2002;204:60–2.

Giugliano G, Pasquali D, Notaro A, Brongo S, Nicoletti G, D'Andrea F, et al. Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts. Br J Plast Surg. 2003;56:804–9.

Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns. 2014;40(4):583-8.

Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol. 2008;47(2):183-6.

Nedelec B, Shankowsky HA, Tredget EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil. 2000;21:205–12.

Li-Tsang CWP, Lau JCM, Liu SKY. Validation of an objective scar pigmentation measurement by using a spectrocolorimeter. Burns. 2003;29:779–84.

Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. J Burn Care Rehabil. 1995;16:535–8.

Sullivan T, Smith J, Kermode J, Mclver E, Courtemanche DJ. Rating the Burn Scar. J Burn Care Rehabil. 1990;11:256–60.

Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Molecular Med. 2011;17(1-2):113-25.

Copcu E, Sivrioglu N, Oztan Y. Combination of surgery and intralesional verapamil injection in the treatment of the keloid. J Burn Care Rehabil. 2004;25:1–7.

Shanthi FM, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol. 2008;74(4):343-8.

Uzair M, Butt G, Khurshid K, Suhail PS. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Dermatol Online. 2015;6(3):280-4.

Danielsen PL, Rea SM, Wood FM, Fear MW, Viola HM, Hool LC, et al. Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Controlled Trial. Acta Derm Venereol. 2016;96:774–8.

Kant SB, Van den Kerckhove E, Colla C, Tuinder S, Van der Hulst RRWJ, de Grzymala AAP. A new treatment of hypertrophic and keloid scars with combined triamcinolone and verapamil: a retrospective study. Eur J Plast Surg. 2018;41(1):69–80.

Jannati P, Aref S, Jannati AA, Jannati F, Moravvej H. Comparison of Therapeutic Response of Keloids to Cryotherapy Plus Intralesional Triamcinolone Acetonide or Verapamil Hydrochloride. J Skin Stem Cell. 2015;2(1):7-12.

Manuskiatti W, Fitzpatrick RE. Treatment response of keloids and hypertrophic sternotomy scars. Arch Dermatol. 2002;138:1149-55.

Bilal M, Tahmeedullah, Irfanullah, Shah SA. Clinical outcome of intralesional corticosteroid versus intralesional Verapamil in the treatment of post burn Keloid scars of the head and neck region. Pak J Surg. 2013;29(4):263–8.